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a b s t r a c t
The two polyhydroxy surfactants polyglycerol 6-distearate (Plurol®Stearique WL1009 – (PS)) and capry-
lyl/capryl glucoside (Plantacare® 810 – (PL)) are a class of PEG-free stabilizers, made from renewable
resources. They were investigated for stabilization of aqueous solid lipid nanoparticle (SLN) and nanos-
tructured lipid carrier (NLC) dispersions. Production was performed by high pressure homogenization,
analysis by photon correlation spectroscopy (PCS), laser diffraction (LD), zeta potential measurements
and differential scanning calorimetry (DSC). Particles were made from Cutina CP as solid lipid only (SLN)
and its blends with Miglyol 812 (NLC, the blends containing increasing amounts of oil from 20% to 60%).
The obtained particle sizes were identical for both surfactants, about 200nm with polydispersity indices
below 0.20 (PCS), and unimodal size distribution (LD). All dispersions with both surfactants were phys-
ically stable for 3 months at room temperature, but Plantacare (PL) showing a superior stability. The
melting behaviour and crystallinity of bulk lipids/lipid blends were compared to the nanoparticles. Both
were lower for the nanoparticles. The crystallinity of dispersions stabilized with PS was higher, the zeta
potential decreased with storage time associated with this higher crystallinity, and leading to a few, but
negligible larger particles. The lower crystallinity particles stabilizedwith PL remained unchanged in zeta
potential (about −50mV) and in size. These data show that surfactants have a distinct inﬂuence on the
particle matrix struture (and related stability and drug loading), to which too little attention was given
by now. Despite being from the same surfactant class, the differences on the structure are pronounced.
They are attributed to the hydrophobic–lipophilic tail structurewith one-point anchoring in the interface
(PL), and the loop conformation of PS with two hydrophobic anchor points, i.e. their molecular structure
and its interaction with the matrix surface and matrix bulk. Analysis of the effects of the surfactants on
the particle matrix structure could potentially be used to further optimization of stability, drug loading
and may be drug release.
. Introduction
Lipid nanoparticles were developed in the last decade of the
ast century as alternative carrier system to emulsions, liposomes
ndpolymeric nanoparticles (Lucks andMüller, 1996;Mehnert and
äder, 2001; Müller et al., 2000a,b, 1995). Solid lipid nanoparti-les (SLN) and nanostructured lipid carriers (NLC) are the two main
ypes of lipid nanoparticles. The research activities in SLN and NLC
n the last two decades focussed mainly on pharmaceutical non-
ermal administration routes, i.e. parenteral (Blasi et al., 2007; Joshi
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and Müller, 2009; Wissing et al., 2004), peroral (Muchow et al.,
2008; Müller et al., 2006; Sarmento et al., 2007), ocular (Attama
et al., 2007; Ugazio et al., 2002) and pulmonary (Liu et al., 2008)
administration. During the last 5 years SLN and NLC have been
intensively investigated for dermal application because of many
positive features that have been reported after their application to
the skin (Müller et al., 2007, 2002b). Due to the lipid matrix, the
small particle size and related adhesive properties, the residence
time of SLN and NLC on the skin is prolonged. There is a lipid inter-
action of the particle matrix with skin surface lipids, affecting drug
absorption (Lombardi Borgia et al., 2007; Santos Maia et al., 2002).
Occlusive properties, increase in skin hydration, modiﬁed release
of actives, targeting effects to speciﬁc skin strata – especially when
the drug is located at the particle surface – are also positive fea-
tures of lipid nanoparticles (Müller et al., 2007). SLN were found
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Lombardi Borgia et al., 2005; Souto et al., 2004; Stecova et al.,
007). The imperfections and ﬂuid domains in the lipid matrix of
LC show a higher loading capacity for a number of drugs than SLN
nd avoid/minimize potential expulsion of drug during the storage
Mehnert and Mäder, 2001; Pardeike et al., 2009).
Due to the production from physiological and biodegradable
ipids, SLN and NLC exhibit good skin tolerability. Good skin
olerability requires also the use of well tolerated surfactants
r polymeric stabilizers. A variety of different stabilizers have
een used up to now for lipid nanoparticles including ionic (e.g.
odium cholate), non-ionic (e.g. polysorbates), amphoteric surfac-
ants (phospholipids), and polymeric stabilizers (e.g. poloxamers,
olyvinyl alcohols) (Siekmann, 1994; Siekmann and Westesen,
994a,b). Polymeric stabilizers are particularly advisable for der-
al application since they are less likely to penetrate beyond the
tratum corneum and hence, they are less likely to cause skin irri-
ation. However, the use of polymers as only stabilizers sometimes
equires relatively high amounts for effective stabilization of lipid
anoparticles (Siekmann, 1994; Siekmann and Westesen, 1994a).
or example, Siekmann and Westesen (1994a) reported that 2%
w/w) Tyloxapol® were insufﬁcient to stabilize a 10% (w/w) tri-
almitine lipid nanoparticles dispersion.
Non-ionic surfactants being uncharged have a low skin sensi-
ization potential and therefore they are preferentially used for
ermal application. Two main groups of non-ionic surfactants
re the ethylene oxide-based surfactants with polyethylene glycol
PEG) blocks and the polyhydroxy (polyol based) surfactants, hav-
ng a polyhydroxy head group chain. Nowadays cosmetic industry
oves away from ethoxylated surfactants, PEG-free is becoming
quality criterion (Cosmetic Ingredient Reviews, 1999; Johnson,
001; Lanigan and Yamarik, 2001; Tadros, 2005). In addition, with
he increasing awareness of environmental issues the cosmetic
nd pharmaceutical industry has a trend to use excipients made
rom renewable materials. In this sense, there is growing inter-
st in polyhydroxy surfactants as the polyhydroxy head group can
e derived from a naturally occurring carbohydrate. Polyhydroxy
urfactants have been developed substituting ethylene oxide by
ydroxy groups. Linking the hydrophilic and hydrophobic parts
n different ways affects HLB and stabilizing properties of these
olecules.
Typical hydrophilic building blocks in their structure are glyc-
rol, carbohydrates and their alcohols (sucrose, glucose, sorbitol)
nd glycols. The main categories of polyhydroxy surfactants are:
lycolesters, glycerol (and polyglycerol) esters, glucosides (and
olyglucosides), sucrose and sorbitan esters.
Polyhydroxy surfactants have the properties of showing
tronger lipophilicity and hydrophilicity compared to ethoxylated
urfactants. The stronger hydrophilicity results from the hydroxy
roups in the structure providing stronger hydrogen bonds with
ater compared to the oxygen in the PEG. Consequently at high
emperature dehydration of the hydrophilic head group can be
revented. Thus, they have a higher critical ﬂocculation temper-
ture. Fatty acid or alcohol chains as hydrophobic part of the
olecule are more hydrophobic than the propylene oxide chain in
.g. PEG-containing poloxamers. In addition, these chains are able
o anchor in the surface of oil droplets or lipid nanoparticles. Addi-
ional reasons for the increasing interest in these molecules can be
heir minor susceptability to pH changes and electrolyte presence
ompared to ethoxylated stabilizers (Söderman and Johansson,
999). Polyhydroxy surfactants possess therefore favourable tech-
ological and dermatological properties, which is why they are
eanwhile often used in dermal formulations. Therefore theywere
nvestigated in this study for their ability to stabilize lipid nanopar-
icles, both SLN and NLC.
Besides the physical stability, the stabilizers can have effects
n the crystallinity and the kinetics of polymorphic transitions ofPharmaceutics 406 (2011) 163–172
lipid after crystallization of nanoparticles (Garti and Yano, 2001).
Previous investigations on tripalmitin nanoparticles indicated that
rigid stabilizer chains are needed to induce crystallization of tri-
palmitin at higher temperatures (Bunjes et al., 2002). The inﬂuence
of stabilizers onto the crystallization is particularly important in the
formulation of lipid nanoparticles made from low melting lipids.
These nanocarriers can be interesting for the processing and the
formulation of temperature-sensitive actives such as peptides and
proteins, excluding the use of high melting lipids. Additionally,
studies about the effect of stabilizers on the crystallization pro-
cess and crystalline structure of the resulting particle matrix may
provide insight into the interaction of the dispersed lipid and the
stabilizer used (Souto, 2005).
The ﬁrst aim of the present study was to evaluate the ability
of polyhydroxy surfactants to create small sized lipid nanopar-
ticle dispersions with narrow size distribution. Two surfactants
with basically different structures having glycerol and glucose as
hydrophilic groups (polyglycerol versus polyglucoside chain),were
used in this study (Table 1). Particle formation was systematically
studied using cetyl palmitate as solid lipid only (SLN) and also using
mixtures of this solid lipid with increasing amounts of Miglyol 812
(NLC). Secondly, the inﬂuence of the surfactant onto the physical
stability and the crystalline state of the particle matrix was investi-
gated. This should provide information about the stabilizing ability,
and towhich extent the twodifferent surfactants inﬂuence the lipid
structure of the particles, in comparison to each other and to bulk
lipid.
2. Materials and methods
2.1. Materials
For the production of the lipid nanoparticles, the solid lipid
cetyl palmitate (Cutina® CP) was kindly provided by Cognis (Düs-
seldorf, Germany). The medium chain triglyceride oil (Miglyol®
812) was purchased from Caelo GmbH (Hilden, Germany). Polyg-
lycerol 6-distearate(Plurol®Stearique WL1009 (PS)) was kindly
provided by Gattefosee (Weil am Rhein, Germany) and capry-
lyl/capryl glucoside(Plantacare® 810 (PC)) by Cognis (Düsseldorf,
Germany).The puriﬁed water was obtained by reverse osmosis
from a Milli Q Plus, Millipore system (Schwalbach, Germany). All
chemicals were used directly as received without further puriﬁca-
tion.
2.2. Methods
2.2.1. Characterization of the bulk lipid material
Differential scanning calorimetry (DSC) was employed to inves-
tigate the effect on the crystalline structure after inclusion of oil
into the solid lipid. In order to mimic the production conditions
of NLC, the bulk mixtures of solid lipid and oil at different ratios
(Table 2) were heated up to 75 ◦C, kept at that temperature for 1h
and subsequently cooled to room temperature. This imitates the
production process of lipid nanoparticles by homogenization in the
melted condition, and the subsequent cooling and recrystallization.
These tempered lipid blendswere then investigatedusing aMettler
DSC 821e apparatus (Mettler Toledo; Gießen, Switzerland) using
accurately weighed samples of 1–2mg.
2.2.2. Preparation of lipid nanoparticles
The total amount of lipid phase (solid lipid, oil) was keptconstant in all lipid nanoparticle suspensions (10%, w/w). SLN con-
tained solid lipid only (Cutina CP)while inNLC a portion of the solid
lipid has been replaced by oil (Miglyol® 812). The lipid nanoparti-
cles in suspension were stabilized using 1% (w/w) of polyhydroxy
surfactants, either PS or PL. Table 3 provides the composition of
A. Kovacevic et al. / International Journal of Pharmaceutics 406 (2011) 163–172 165
Table 1
Trade names, chemical names and struture of polyhydroxy surfactants used for the preparation of the lipid nanoparticle dispersions.
Trade name of surfactant Structural formula and chemical name of
surfactant





DSC parameters of the tempered bulk solid lipid and bulk lipid blends with increasing oil content.
Lipid Melting temperature [◦C] Onset temperature [◦C] Enthalpy [J/g] Integral (mJ)
Cutina® CP(bulk lipid) 52.44 47.89 220.46 296.52



















o70% Cutina CP+30% Miglyol 812 47.72
60% Cutina® CP+40% Miglyol® 812 46.90
50% Cutina® CP+50% Miglyol® 812 46.07
40% Cutina® CP+60% Miglyol® 812 45.28
he formulations, from SLN (=100% solid lipid) and the NLC with
ncreasing oil content in the lipid blend from 20% Miglyol 812 to
0%.
Preparation of the lipid nanoparticle suspensions was carried
ut by hot high pressure homogenization (HPH). Brieﬂy, the lipid
hase was melted at 75 ◦C and subsequently dispersed by high
peed stirring (8000 rpm for 1min) in the hot aqueous surfactant
olution of identical temperature. The dispersing was performed
sing an Ultra-Turrax (Janke & Kunkel, Staufen, Germany). The
btained pre-emulsion was then subjected to HPH using a Micron
AB 40 (APV Deutschland GmbH, Germany). Five homogenization
ycles at 500bar anda temperatureof75 ◦Cwereapplied.AfterHPH
heobtainedhot o/wnanoemulsionwasﬁlled in silanized transpar-
nt glass vials (glass quality II), which were immediately sealed.
espite using glass quality II, the vials were siliconized to fur-
her minimize the adsorption of nanoparticles onto the walls. This
able 3
omposition of the lipid nanoparticle dispersions (%w/w) producedwith Plurol Stearique®
f pure solid lipid. i.e. PS (SLN) and PL (SLN), or contained an increasing amount of Miglyo
Formulation Cutina® CP Miglyol® 812 Plurol Ste
PS (SLN) 10.0 – 1.0
PS (20) 8.0 2.0 1.0
PS (30) 7.0 3.0 1.0
PS (40) 6.0 4.0 1.0
PS (50) 5.0 5.0 1.0
PS (60) 4.0 6.0 1.0
PL (SLN) 10.0 – –
PL (20) 8.0 2.0 –
PL (30) 7.0 3.0 –
PL (40) 6.0 4.0 –
PL (50) 5.0 5.0 –




adsorption is known to promote aggregation by fusion of adsorbed
nanoparticles. The vials were placed into a water bath adjusted to
20 ◦Ctocontrol thecooling rateof thenanoemulsionsand theveloc-
ity of crystallization. To investigate the physical stability, the lipid
dispersionswere storedat25±2 ◦C for aperiodof90days. The sam-
ples were analyzed at previously determined time intervals (day 0,
1st, 30th and 90th day).
2.2.3. Particle size analysis
Particle size analysiswas performed by dynamic light scattering
(DLS), also knownas photon correlation spectroscopy (PCS), using a
Malvern Zetasizer Nano ZS (Malvern Instruments, UK). Prior to the
measurements all samples were diluted using ultra-puriﬁed water
to yield a suitable scattering intensity. DLS data were analyzed
at 25 ◦C using the general purpose mode. DLS yields the hydro-
dynamic diameter (intensity weighted mean diameter, z-average,
WL 1009 (PS) or producedwith Plantacare® 810 (PL). The particlematrix consisted
l 812 oil from 20% to 60%. e.g. PS (20) to PS (60).
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-ave) and the polydispersity index (PI) as a measure of the width
f the particle size distribution. The PI ranges from 0 to 1 while
onodisperse populations yield theoretically a PI of 0. Very nar-
ow distributed particle populations possess PI values of about
.02–0.05, o/w emulsions for parenteral nutrition by intravenous
nfusion typically from 0.10 to 0.25. The z-average and PI of the
nvestigated samples were obtained by calculating the average of
0measurements at an angle of 173◦ in 10mmdiameter disposable
lastic cells.
The measuring range of the Zetasizer is from approximately
nm to 6m. Therefore, in order to detect potential larger par-
icles and oil droplets static light scattering (SLS), also known as
aser diffractometry (LD), with a measuring range up to 2000m
as applied as additional characterizationmethod using aMalvern
astersizer 2000 (Malvern Instruments, UK). SLS data were ana-
yzed using the Mie theory with the optical parameters 1.456 (real
efractive index) and 0.01 (imaginary refractive index). The SLS
ata yield a volume distribution. The volume weighted diame-
ers d(v) 50%, d(v) 90% and d(v) 99% were used to characterize the
ispersions. The diameter values indicate the percentage of par-
icles possessing a diameter equal or lower than the given values
Rawle). For example, d(v) 99% means that 99% of the volume of
he particles is below the given size. Soniﬁcation prior and during
he measurement was not performed to avoid the destruction of
ossible aggregates within the sample. Such aggregates are a sen-
itive marker for insufﬁcient stabilization, and will mainly affect
he diameters 90% and 99%.
.2.4. Zeta potential analysis
The zeta potential was determined by the measurement of
he electrophoretic mobility using a Malvern Zetasizer Nano ZS
Malvern Instruments, UK). The ﬁeld strength appliedwas 20V/cm.
he conversion into the zeta potential was performed using the
elmoltz–Smoluchowski equation:
= EM × 4
ε
here  is zeta potential, EM the electrophoretic mobility,  the
iscosity of the dispersionmedium and the dielectric constant ε. To
void the ﬂuctuation in the zeta potential due to variations in the
onductivity of puriﬁedwater,which can range from1 to 10S/cm,
he conductivity of the water was adjusted to 50S/cm using 0.9%
w/v) sodium chloride solution. The pH during the measurements
as in the range of 5.5–6.0. Each sample was measured three times
nd mean value and standard deviation (SD) are presented.
.2.5. Differential scanning calorimetry investigations of the lipid
anoparticle suspensions
Thermal analysis was performed using again the Mettler DSC
21e apparatus (Mettler Toledo, Gieben, Switzerland). The amount
f the sample (aqueous dispersion) was calculated this way, that it
ontained approx. 1–2mg lipid (accurately weighted). For a 10%
LC dispersion this is approx. 10–20l, which were placed in
0l aluminum pans. The heating runs were performed from 20
o 90 ◦C at a heating rate of 10Kmin−1. An empty aluminum pan
as used as reference. Onset temperature, melting point, enthalpy
nd integralwerecalculatedby theSTARe Software (Mettler Toledo,
witzerland). Furthermore, the recrystallization index (RI) i.e. per-
entage of re-crystallized solid lipid related to initial solid lipid
oncentration (not total lipid concentration of solid and liquid
ipid!) was calculated using the following equation (Freitas and
üller, 1999):
I (%) = Haqueous SLNorNLCdispersion
Hbulkmaterial × concentration lipidphase
× 100Pharmaceutics 406 (2011) 163–172
where Haqueous SLN or NLC dispersion and Hbulk material are the melt-
ing enthalpy (J/g) of SLN and NLC dispersion and bulk material,
respectively. The concentration of the lipid phase is given in parts
solid lipid in the total suspension (e.g. 10% suspension is 10/100
parts =0.1, a 10% NLC suspension composed of 8% solid lipid and
2% oil is = 0.08). In case the RI of the tempered bulk material is
calculated, the concentration is =1.
2.2.6. Light microscopy
SLS measurements can overlook a small number of larger par-
ticles besides a small-sized main particle population (Keck and
Müller, 2008). Therefore to detect potential instability and aggre-
gates during storage, the dispersions were additionally monitored
using a light microscope (Orthoplan Leitz, Wetzlar, Germany).
The microscope was equipped with a CMEX 3200 digital camera
(Euromex microscopes, Arnheim, Netherlands) connected to the
Image Focus software version 1.3.1.4. Microscopic pictures were
taken from the undiluted lipid nanoparticle dispersions to increase
the probability of detecting even a few large aggregates. Aim was
not to analyze the nanoparticles themselves, because they are
below the detection limit (about 500nm) of the microscope. Mag-
niﬁcations applied were 160, 400, 630 and 1000 fold.
3. Results and discussion
3.1. Characterization of bulk lipid material
A DSC study was performed to understand the blending
behaviour of the solid lipid Cutina CP with increasing amounts
of oil, i.e. Miglyol 812. It should provide information about the
inﬂuence of the oil onto the melting behaviour and change in crys-
tallinity to obtain information on the inclusion of the oil into the
bulk of solid lipid. The thermo-analytical parameters as derived
from the DSC measurements are given in Table 2. Cetyl palmitate
revealed two peaks at 38.94 ◦C (small peak) and 52.42 ◦C (main
peak) (Fig. 1). Based on literature data, the ﬁrst peak with lower
melting point is attributed to the -polymorphic form (thermody-
namic instable modiﬁcation) whereas the second peak belongs to
the -polymorphic form (stable modiﬁcation) (Saupe et al., 2005).
Cetyl palmitate and medium chain triglycerides exhibit a
good miscibility and thus a homogeneous lipid matrix should be
obtained in the NLC. The DSC thermograms show that above 20%
oil, the separate peak of the -modiﬁcation disappears (Fig. 1,
middle), at the same time the peak broadens (increase in dif-
ference between melting temperature and onset) and the peak
height (also area under the curve) decreases, hence the crys-
tallinity is reduced (Fig. 1, middle and lower). This supports
that the oil is molecularly dispersed in the lipid blend, at least
at lower concentrations, which creates distortion in the lipid
matrix.
A melting point depression occurs, if a second compound
is dissolved in a ﬁrst compound. Therefore the melting point
determination is also used for purity analysis of materials. With
increasing concentration of the second compound, the melting
point decreases in a linear fashion. A decreasing melting point, and
onset temperature, was observed with increasing oil content in the
lipid blends (Table 2). The decrease was linear up to 60% oil in the
lipid blend, indicating good miscibility.
With 20% (w/w) of oil the difference between the melting and
the onset temperatureswas 8.82 ◦C and increased to 11.48 ◦Cwhen
the blends contained 60% (w/w) of the oil. Therefore, for the given
concentration range the depression of the onset temperatures did
not occur in a linear fashion. There is a strong decay up to 20% and
30% oil content, then the decay ﬂattens with increasing contents of
oil (Fig. 2). The broadening of the peak is caused by amore complex,
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fig. 1. DSC heating thermograms of tempered bulk solid lipid Cutina CP and tem-
ered lipid blends with increasing Miglyol 812 content from 20% to 60%.
istorted structure of the lattice, the ﬂattening of the onset tem-
erature decay might indicate, that one approaches the maximum
olubility of the oil in the solid lipid.
Distortion of the lattice and reduced crystallinity is clearly seen
y the decrease in melting enthalpy of the blends with increasing
il content compared to thepure solid lipid. The enthalpydecreases
rom about 220 J/g to 55 J/g at 50% oil content in the blend, accom-
anied by a decrease in crystallinity from 100% to 25.3% (Table 2).
ig. 2. Decrease of melting temperature and onset temperature, and increase of
idth betweeen these two temperatures at increasing oil content of the bulk lipids
rom 0% to 60%, as deteremined by DSC (data from Table 1).Pharmaceutics 406 (2011) 163–172 167
Interestingly, the crystallinitydoesnot furtherdecreasewhenmov-
ing from50%oil to 60% oil, it stays unchanged at 25.3%. This can also
seen as indication that one approaches the solubility limited of the
oil in the blend.
According to Müller et al. at low oil concentration, the oil
molecules are distributed within the solid lipid matrix and the
imperfect type of NLC is obtained (Müller et al., 2002a). In case
the oil exceeds its solubility in the solid lipid, the multiple type
of NLC is formed. The oil precipitates separately e.g. in liquid
nanocompartments within the lipid particle matrix. This occurs
during the cooling process. At high temperatures, complete mis-
cibility occurs between the melted solid lipid and oil. During the
cooling down process the solubility of the oil in the solid lipid is
exceeded. Therefore, due to the miscibility gap phase separation
occurs. The oil precipitates in the form of ﬁne droplets being incor-
porated into the solid lipid matrix during the cooling process of
NLC. Based on the DSC bulk data, a phase separation cannot be
excluded when producing NLC with the high oil concentrations,
especially because crystallization processes in the nanodimension
differ from bulk crystallisation. Examples are the reduction of the
melting temperature (Gibbs–Thomson effect (Perez, 2005)) or the
lack of re-crystallization by formation of supercooled nanoparti-
cles.
There is a kind of controverse discussion, where the phase
separated oil is located. Müller et al. (2002a) and zur Mühlen
and Mehnert suggest location in form of nanocompartments
throughout the solid lipid matrix (original model). However, the
nanocompartments might be enriched in the core or the shell
(Saupe et al., 2005) or located at the surface (oil layer on surface?).
There are also spoon-like structures suggested (Jores et al., 2005,
2004). It is outside the scope of this article to discuss in detail the
physics behind the various theories. At least it can be stated, that
the location will deﬁnitely differ depending on the chemical nature
of solid and liquid lipid, the solubility/miscibility of lipids in each
other, production conditions, and interfacial tensionsbetween lipid
andwater phase (interfacial energies). As conclusion, the described
structures could exist besides each other, depending on the lipids
used.
3.2. Particle size analysis and physical stability
Table 3 gives an overview of the formulations produced. The
total amount of lipid phase was kept constant (10%, w/w), the per-
centage of oil in the lipid matrix of the NLC was increased from 20%
to 60%, according to the investigated bulk lipids. The particle sizes
for all formulations have been evaluated by DLS and SLS imme-
diately after production and during a storage period of up to 90
days.
Under optimized production conditions (500 bar, ﬁve homog-
enization cycles, 75 ◦C) small lipid nanoparticles with a relatively
uniform size distribution were obtained. Figs. 3 and 4 show the
obtained results. The mean DLS particle diameters were around or
below 200nm with PI values below 0.2 indicating monomodal size
distributions. During the observation period of 90 days the mean
diameters and PI values did practically not change. This indicates
good physical stability of the lipid nanoparticles stabilized with
both polyhydroxy surfactants.
Cetyl palmitate is a wax produced by catalytic esteriﬁcation of
fatty alcohol (cetyl alcohol) and fatty acids (palmitic acid) (Saupe
et al., 2005). It was suggested that surface active partial glycerides
(mono-, and diglycerides and their mixtures) facilitate emulsi-
ﬁcation and form more rigid surfactant ﬁlms around the lipid
nanoparticles and thus improve long termphysical stability (Bunjes
et al., 2003; Westesen et al., 1993). However, for a relatively pure
cetyl palmitate as used in this study, primarily the surfactant used
is responsible for physically stable lipid nanoparticles (Saupe et al.,
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Fig. 3. PCS data (diameter and PI) and LD data (diameters d(v) 50%, d(v) 90% and d(v) 99%) of the formulations stabilized with PS (polyglyceryl 6-distearate) plotted as function
of time (0, 1, 30, 90 days).
Fig. 4. PCS data (diameter and PI) and LD data (diameters d(v) 50%, d(v) 90% and d(v) 99%) of the formulations stabilized with PL (caprylyl/capryl glucoside) plotted as function
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005). The mean diameters reﬂect the ability of the polyhydroxy
urfactants for stabilization.
All lipid nanoparticles stabilized with PS (Plurol Stearique,
olyglycerol 6-distearate) had a mean diameter of about 200nm,
hereas themeandiameter of the samples stabilizedwith PL (Plan-
acare 810, caprylyl/capryl glucoside)was around170nm. PI values
round 0.2 indicate a relatively narrowparticle size distribution for
he both surfactants. The oil content did not inﬂuence the mean
article size. The explanation is that during the production of NLC,
he lipid mixture was in the melted state. The viscosity of melted
ure cetyl palmitate and the cetyl palmitate/oil blends at this tem-
erature is not that different. Applying the same homogenization
nergy, NLC containing different amounts of oil should yield the
ame mean particle size (Jores et al., 2004). The ﬁnal size obtained
ay depend on various factors, such as the chemical structure of
he lipids, the surfactants used, aswell as their chemical interaction
Lin et al., 2007). For example, the surfactants need to be able to sta-
ilize fast the formeddropletswhen they leave thehomogenization
ap, to avoid subsequent coalescence. Obviously the polyhydroxy
urfactants are able to do this, whereas PL yields smaller particles
DLS data).
SLS and light microscopy were applied as additional methods
o check for the absence of aggregates. Immediately after pro-
uction a unimodal, relatively narrow particle size distribution
as observed by SLS (curves not shown). The diameters d(v) 50%
ere below 200nm, the diameters d(v) 99% as sensitive parame-
er for the presence and quantity of larger particles below 600nm
Figs. 3 and4). Thus, thepresenceofmicroparticles in these samples
an be excluded, to be precise: are below the detection limit. These
ata were in agreement with light microscopy (data not shown).
The physical stability was monitored for 90 days. In the formu-
ations stabilized with PS the d(v) 50% and d(v) 99% were below
00nm and 600nm, respectively at the production day. At day
0, d(v) 99% was still below 600nm for an oil content up to 30%
w/w). Increasing the oil content from 40 to 60% (w/w) led to an
ncrease of d(v) 99% (Fig. 3). Agglomerates found after 90 days in
hese samples were also conﬁrmed by light microscopy. However,
he degree of aggregation was small, as only the diameter d(v) 99%
s above 1m, whereas d(v) 50% and d(v) 90% are still below 1m.
he observed slight destabilization seems to result from the expul-
ion of oil from the lipid matrix during the storage. Increasing the
il content from 40 to 60% (w/w) resulted only partially into incor-
oration into the solid lipid matrix. This was conﬁrmed by DSC
ata (cf. below). Similar results were reported for NLC based on the
ixture monocaprate (solid lipid) and medium chain triglycerides
hich are stabilized with Polysorbate 80 as surfactant (Lin et al.,
007). In contrast to this, all lipid nanoparticle dispersions were
erfectly stable when stabilized with PL (Fig. 4).
The physical stability has also been monitored by macro-
copic observations. Systems remained stable with a milky-like
ppearance without any particle sedimentation during the stor-
ge. The absence of agglomerates after 90 days in these
amples was also conﬁrmed by light microscopy (data not
hown).
.3. Zeta potential (ZP) analysis
Zeta potentials of the formulations have been evaluated imme-
iately after production (day 0) and after storage of 90 days.
mmediately after production the zeta potentials were in the range
rom −30.0 to −52.0mV for all samples indicating good physical
tability (Fig. 5). From the literature, a minimum zeta potential of
igher than −60.0mV is required for excellent physical stability
nd of higher than −30.0mV for good physical stability (Müller,
996; Riddick, 1968).Pharmaceutics 406 (2011) 163–172 169
Polyhydroxy surfactants are nonionic steric stabilizers, there-
fore at the ﬁrst glance onewould rather expect a low zeta potential.
The measured zeta potential originates from the height of the
Nernst potential (surface charge) and the additional charges cre-
ated by adsorbed ions or surfactants or stabilizer molecules in the
Stern layer. The SLN produced with solid lipid only possessed a ZP
of −30mV when stabilized with PS, but of −48mV when stabilized
with PL. It is assumed, that the major charge of the PS-stabilized
nanoparticles originates from the surface, e.g. dissociated free fatty
acids, some contribution potentially from salts present as impurity
in the surfactant. The PL-stabilized nanoparticles possess the same
particle composition (Cutina CP), but a higher ZP. This higher ZP is
obviously created by the different type of stabilizer. The PL has one
hydrophobic anchor to be embedded in the surface, and one long
hydrophilic tail composed of glucose molecules penetrating into
thewater phase. The glucoseswill strongly interactwithwater, e.g.
attracting potentially negatively charged hydroxyl ions. The PS has
twohydrophobic anchors located at the end of themolecule, polyg-
lycerol in the center. Assuming both lipophilic parts anchored into
the particle surface, the molecule will have a loop structure on the
surface. These differences are considered as cause for the different
ZP values.
With increasing oil content in the particle matrix, the ZP
of the PL-stabilized nanoparticles stays unchanged. It stays also
unchanged during the 90 days of storage, being the reason of the
observed perfect physical stability (cf. Section 3.2).
Interestingly, the ZP of the PS-stabilized nanoparticles increases
with increasing oil content form −32mV (no oil) to about −50mV
(60% oil). Assuming an unchanged situation for the stabilizer layer
on the surface, this increase in the ZP can only originate from an
increase of the surface potential. Obviously there are more charges
on the surface, potential source are free fatty acids contained in the
solid lipid but also in the oil. The oil nanocompartments of NLC can
be embedded into the solid lipid matrix (Müller et al., 2002b) or
to be localised at the surface of solid platelets and the surfactant
layer (Jores et al., 2005). Therefore this increase in zeta potential
can be the result of changes on the NLC surface. These changes
did not occur with PL, this supports the theory that the surfactants
used also affect the structure of the lipid particle matrix, including
localization of oil.
During the storage of 90 days, the zeta potential of the PS-
stabilized NLC decreased for an oil content of 40–60%. Obviously
there must be changes in the composition of particle matrix
and related surface composition and charge. Without additional
investigations, discussing potential reasons would be speculative.
Furthermechanistic investigationsarenecessary for abetterunder-
standing of this effect, because the structural change is obviously
stabilizer-related, as it doesnot occurwithPL. Theunderstandingof
such inﬂuences would allow a more controlled selection of optimal
stabilizers for lipid nanoparticle dispersions in the future.
However, in these PS-stabilized formulations the zeta potential
is still higher than−30.0mVafter 90 days of storage. Hence fromZP
theory, the values are in the range for stable dispersions. Therefore
the slight instability observed in these samples with 40–60% oil
contentmightbedue todestabilizingeffectsnot accessiblebya zeta
potential measurement. It should be pointed out, that the increase
in the diameter 90% is very low, not affecting the use of these NLC
in dermal formulations.
3.4. Inﬂuence of hydrophilic–lipophilic-balance (HLB) of the
stabilizer on size and stabilityThe particle size and the physical stability of a disperse system
are inﬂuenced by many parameters, e.g. type and concentration of
the stabilizer. Up today it is not possible to fully predict the size and
the physical stability without practical investigations. However,
















































nig. 5. Zeta potentials of the formulations stabilized with PS and with PL produced
o 60% (for formulation code and composition cf. Table 3).
arameters e.g. zeta potential and polydispersity are important
ools, as they can indicate good stability at an early stage of the
evelopment. Nevertheless, in the ﬁeld of emulsion formulation,
specially in the cosmetic ﬁeld, another possibility to obtain ﬁnely
ispersed and physically stable emulsions is the estimation of the
required HLB”. This means, that the HLB of the stabilizer should
atch the required HLB of the inner phase as close as possible.
uch a required HLB can be either calculated using Griﬁnth equa-
ion or by assessing the values provided by manufactures. For the
ipids used in this study the required HLB is 10 for the solid lipid
nd 5 for the liquid lipid. Hencewith an increasing amount of liquid
ipid the HLB decreases. The surfactants used in this study possess
ifferent HLB values. The HLB of PS is 9–10 and the HLB of PL is
5–16 (cf. Table 1). Thus, from theory, best results (smallest size,
ighest stability) would be expected for the SLN and the NLC con-
aining 20% oil stabilized with PS (HLB 9–10), respectively. Indeed,
hese formulations are physically stable, whereas the NLC contain-
ng more oil, e.g. 40–60% (required HLB of these formulations is
–7) are less stable (cf. Fig. 4). However, the size of the SLN stabi-
ized with PL is smaller than the size of the SLN stabilized with PS,
ven though the HLB of PL is much higher and thus not as close
o the required HLB of the lipid phase as PS (cf. Figs. 3 and 4).
lso for the NLC with high oil content the lower and more close
LB of PS was less sufﬁcient in stabilizing the NLC, whereas the
igh HLB surfactant PL, could stabilize all lipid nanoparticle sys-
ems investigated sufﬁciently (cf. Figs. 3 and 4). Thus, in conclusion
he “requiredHLB” theory cannot be used to explain the differences
etween the two stabilizers investigated. In fact, results prove that
he development of a ﬁnely dispersed and physically stable lipid
anoparticle system is very complex, not yet fully understood, and
annot only be reached by simply using the “requiredHLB”method
lone.
.5. Differential scanning calorimetry investigations
Table 4 gives an overview of the DSC data of SLN and of
LC dispersions, which have been stored for a period of 90
ays at controlled room temperature. After this time, an equilib-
ium condition can be assumed. The nanonized cetyl palmitate
s distinctly below the melting temperature of the bulk mate-
ial (melting point depression by about 4 ◦C). This phenomenon
s described by the Gibbs–Thompson effect, i.e. the larger ratio
f speciﬁc surface area to volume of particle with a smaller
ize when compared to bulk material (Perez, 2005). A shift
f the melting point to lower temperatures with decreasing
ean particle size was also observed for Dynasan® 116 dis-
ersions stabilized with Tyloxapol® (Souto, 2005). Beside the
mall particle size, the potential inﬂuence of surfactants should
ot to be neglected. Depending on the lipophilicity, the sur-soild lipid only (SLN) or mixtures with increasing percentage of Miglyol from 20%
factants partition between water phase, interface and the lipid
phase. Surfactant in the lipid phase can distort crystallization
and affect the melting temperature. Interestingly, the melt-
ing point is the same for SLN stabilized with PS or with PL,
i.e. for nanoparticles made from solid lipid only. The same
applies for the NLC regarding melting point, but also the onset
temperature.
However, the situation is different for the recrystallisation index
RI (cf. Section 2.2.5). For the SLN, the RI is reduced to about 60%
when stabilized with PS, but reduced to only 32% in case of PL
as stabilizer (Table 4). The same is valid for all NLC. The ones
stabilized with PL possess much less crystallinity. PS stabilized
NLC with 50% oil in the matrix (PS (50)) have a RI of 12%, the
corresponding PL (50) dispersion shows no melting event any
more, i.e. the dispersion is a supercooled nanoemulsion (Table 4
and Fig. 6). At 60% oil in the particle matrix, both formulations
are not solid any more. This shows ﬁrstly the strong inﬂuence
of the type of surfactant on the crystallinity, and secondly is a
nice example for differences in re-crystallization between bulk and
nanomaterial.
The decreasing of melting peak and melting enthalpy, i.e. dis-
tortion of the crystalline lattice in NLC after oil addition, is identical
to the distortion of crystalline structure of lipid blends in the
bulk state, but more pronounced in the nano dimension. This less
ordered crystalline lipid matrix of NLC is favourable for encapsu-
lating more active (higher loading).
The differences in the shapes of DSC curves in Fig. 6 (PS versus
PL) show that the internal structure of lipid nanoparticles is inﬂu-
enced by the type of polyhydroxy surfactants used. It is known that
the surfactants can have impact on the resulting structure of dis-
persed phases. In o/w emulsions containing emulsiﬁers with long
saturated fatty acid chains, the increased crystallization tendency
of the dispersed phase has been correlated with the formation
of emulsiﬁers templates in the oil droplets. Investigations on tri-
palmitin nanoparticles indicated that rigid long saturated alkyl
chains of surfactants (Polysorbate 80) are necessary to induce crys-
tallization. PS (polyglycerol 6-distearate) the surfactant containing
long saturated alkyl chain (solid surfactant!) might initiate crys-
tallization of lipid matrix of nanoparticles, explaining the higher
RI values. Due to the afﬁnity of polyglycerol 6-distearate to cetyl
palmitate, a small portion of the surfactant molecules localize in
the lipid phase (partitioning coefﬁcient) and thus promote re-
crystallization of the lipid. A part of the stabilizer is included into
the lipid matrix of nanoparticles, stabilizers are not only attached
onto the surface. Similar results have been obtained for SLN con-
taining tripalmitate as solid lipid and lecithin as emulsiﬁer (Ahlin
et al., 2000).
In contrast, PL (caprylyl/capryl glucoside) with short hydropho-
bic alkyl chains (liquid surfactant!) is less hydrophobic, and thus
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Table 4
DSC parameters of the lipid nanoparticle dispersions produced with PlurolStearique® WL 1009 (PS) or produced with Plantacare® 810 (PL), composition and sample code cf.
Table 3.
Formulation Melting temperature [◦C] Onset temperature [◦C] Enthalpy [J/g] RI [%] Integral [mJ]
PS (SLN) 48.80 43.80 13.3 60.33 190.55
PS (20) 47.97 43.61 8.15 36.97 133.40
PS (30) 46.98 43.90 4.92 22.32 80.56
PS (40) 45.77 42.73 4.32 19.59 86.52
PS (50) 45.55 42.18 2.70 12.24 46.89
PS (60) No melting event
PL (SLN) 48.79 44.6 7.12 32.30 130.89
PL (20) 47.35 42.42 5.16 23.40 88.33
PL (30) 46.78 42.06 3.83 17.37 77.35
PL (40) 47.15 45.30 0.46 2.08 9.37
PL (50) No melting event





























































































































Fig. 6. DSC heating scans of the aqueuos lipid nanoparticle dispersions at d
ight locate less in the lipid phase, as it is too mobile in order
o induce crystallization of lipid in NLC containing a high oil con-
ent. This surfactant probably forms rather a more “ﬂuid”, less
igid membrane around nanodroplets with a low microviscos-
ty. Therefore, polyglycerol 6-distearate with a “solid lipid tail”
n the structure leads to a different interaction with lipid matrix
olecules, than the “liquid lipid tail” surfactant (caprylyl/capryl
lucoside).
The onset and the melting process of SLN and NLC occur at
he temperature above 40 ◦C. This is especially important for lipid
anoparticles for dermal application of pharmaceutical and cos-
etic actives. The particles should remain in the solid state when
pplied.
The PS stabilized NLC possess a higher crystallinity than the
nes with PL, this can cause phase separation, e.g. drug expulsion
ut also potentially expulsion/separation of oil from solid lipid.
hus could lead to changes in the composition of the surface, and
elated changes in Nernst and zeta potential. The zeta potentials
ecreased during storage. Such phenomena might also promote
ridging between particles.9080706050403020
Temperature (°C)
(scan from 20 to 90 ◦C, scan rate 10Kmin−1, formulation code cf. Table 3).
4. Conclusions
Both polyhydroxy surfactants in the concentration of 1% (w/w)
led to SLN and NLC with a mean diameter of about 200nm. SLN
and NLC with an oil content up to 30% (w/w) were physically stable
over the investigated period of 90 days. However, increasing the oil
content to 40% and higher led to a slight increase in larger particles
(d(v) 0.99) inNLCstabilizedwithPS (polyglycerol6-distearate). This
effect was attributed to the higher crystallinity and related expul-
sion effects. The formulations stabilized with PL (caprylyl/capryl
glucoside) were perfectly stable at each oil content. However, NLC
with an oil content of 50% or higher and of 60% (PS and PL, respec-
tively)were not solid anymore – in contrast to the bulk lipid blends.
This shows the limitation in nanostructuring of NLC by oil addition,
and the different re-crystallization properties in the nanodimen-
sion.
It canbe concluded that the crystallization tendencyof theparti-
cles increaseswith the length of the saturated hydrophobic chain of
polyhydroxy surfactant. These observations suggest that the crys-
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urfactant structure but also the interaction of the surfactant and
ipid matrix molecules.
In overall conclusion polyhydroxy surfactants proved suitable
or the stabilization of SLN and NLC dispersions, they are there-
ore an interesting newly applied class of stabilizers for future
ermal products. They can inﬂuence the crystalline state of the
ipidmatrix innanoparticles and for a successful formulationdevel-
pment, this parameter needs to be investigated. Furthermore, it
ight be a helpful tool to develop NLC with a “tailor-made” crys-
alline state, resulting loading capacity and release proﬁle in the
uture.
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